Lowest-Rated StocksLowest-RatedNASDAQ:IGMS IGM Biosciences (IGMS) Stock Price, News & Analysis $1.28 +0.01 (+0.79%) Closing price 07/23/2025 04:00 PM EasternExtended Trading$1.27 -0.01 (-0.78%) As of 07/23/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About IGM Biosciences Stock (NASDAQ:IGMS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get IGM Biosciences alerts:Sign Up Key Stats Today's Range$1.27▼$1.2850-Day Range$1.08▼$1.3652-Week Range$0.92▼$22.50Volume195,890 shsAverage Volume377,219 shsMarket Capitalization$76.52 millionP/E RatioN/ADividend YieldN/APrice Target$5.50Consensus RatingReduce Company Overview IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California. Read More IGM Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks92nd Percentile Overall ScoreIGMS MarketRank™: IGM Biosciences scored higher than 92% of companies evaluated by MarketBeat, and ranked 86th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingReduce Consensus RatingIGM Biosciences has received a consensus rating of Reduce. The company's average rating score is 1.90, and is based on no buy ratings, 9 hold ratings, and 1 sell rating.Amount of Analyst CoverageIGM Biosciences has received no research coverage in the past 90 days.Read more about IGM Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for IGM Biosciences are expected to grow in the coming year, from ($3.35) to ($0.96) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IGM Biosciences is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IGM Biosciences is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIGM Biosciences has a P/B Ratio of 1.56. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about IGM Biosciences' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.36% of the float of IGM Biosciences has been sold short.Short Interest Ratio / Days to CoverIGM Biosciences has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in IGM Biosciences has recently decreased by 45.42%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIGM Biosciences does not currently pay a dividend.Dividend GrowthIGM Biosciences does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-1.08 Percentage of Shares Shorted2.36% of the float of IGM Biosciences has been sold short.Short Interest Ratio / Days to CoverIGM Biosciences has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in IGM Biosciences has recently decreased by 45.42%, indicating that investor sentiment is improving significantly. News and Social Media2.8 / 5News Sentiment0.97 News SentimentIGM Biosciences has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for IGM Biosciences this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added IGM Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, IGM Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,377.00 in company stock.Percentage Held by Insiders57.00% of the stock of IGM Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions42.79% of the stock of IGM Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about IGM Biosciences' insider trading history. Receive IGMS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IGM Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address IGMS Stock News HeadlinesAnalysts Set IGM Biosciences, Inc. (NASDAQ:IGMS) PT at $5.50July 23 at 4:23 AM | americanbankingnews.comIGM Biosciences Enters Definitive Merger Agreement with Concentra Biosciences for Acquisition - NasdaqJuly 3, 2025 | nasdaq.comMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks. | American Alternative (Ad)IGM Biosciences Enters into Agreement to Be Acquired by Concentra Biosciences for $1.247 in Cash per Share Plus a Contingent Value Right - Seeking AlphaJuly 3, 2025 | seekingalpha.comIGMS Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of IGM Biosciences, Inc. is Fair to Shareholders - MorningstarJuly 3, 2025 | morningstar.comMIGM Biosciences Shares Surge on Takeover Agreement with ConcentraJuly 2, 2025 | msn.comIGMS Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of IGM Biosciences, Inc. is Fair to ShareholdersJuly 1, 2025 | businesswire.comIGM Biosciences Enters into Agreement to Be Acquired by Concentra Biosciences for $1.247 in Cash per Share Plus a Contingent Value RightJuly 1, 2025 | globenewswire.comSee More Headlines IGMS Stock Analysis - Frequently Asked Questions How have IGMS shares performed this year? IGM Biosciences' stock was trading at $6.11 at the beginning of the year. Since then, IGMS shares have decreased by 79.1% and is now trading at $1.28. How were IGM Biosciences' earnings last quarter? IGM Biosciences, Inc. (NASDAQ:IGMS) released its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.41) by $0.45. The firm had revenue of $0.50 million for the quarter, compared to the consensus estimate of $4.25 million. IGM Biosciences had a negative trailing twelve-month return on equity of 317.97% and a negative net margin of 7,417.79%. When did IGM Biosciences IPO? IGM Biosciences (IGMS) raised $125 million in an initial public offering on Wednesday, September 18th 2019. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Jefferies, Piper Jaffray, Stifel and Guggenheim Securities acted as the underwriters for the IPO. How do I buy shares of IGM Biosciences? Shares of IGMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of IGM Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that IGM Biosciences investors own include American Water Works (AWK), Waste Connections (WCN), Humana (HUM), The RMR Group (RMR), DiamondRock Hospitality (DRH), AU Optronics (AUOTY) and Voyager Therapeutics (VYGR). Company Calendar Last Earnings5/13/2025Today7/24/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IGMS CIK1496323 Webigmbio.com Phone650-965-7873FaxN/AEmployees190Year Founded2010Price Target and Rating Average Price Target for IGM Biosciences$5.50 High Price Target$20.00 Low Price Target$1.50 Potential Upside/Downside+329.7%Consensus RatingReduce Rating Score (0-4)1.90 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($3.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$195.79 million Net Margins-7,417.79% Pretax Margin-7,417.79% Return on Equity-317.97% Return on Assets-71.43% Debt Debt-to-Equity RatioN/A Current Ratio5.71 Quick Ratio5.71 Sales & Book Value Annual Sales$2.68 million Price / Sales28.55 Cash FlowN/A Price / Cash FlowN/A Book Value$0.82 per share Price / Book1.56Miscellaneous Outstanding Shares59,780,000Free Float25,703,000Market Cap$76.52 million OptionableOptionable Beta0.48 Social Links A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:IGMS) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBitcoin just humbled Jeff BezosBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IGM Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IGM Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.